Features of children perinatally infected with HIV-1 surviving longer than 5 years. Italian Register for HIV Infection in Children

Lancet. 1994 Jan 22;343(8891):191-5.

Abstract

Children infected with HIV do not necessarily develop AIDS to a set pattern but can be divided into long-term and short-term survivors. We examined long-term survival in children perinatally infected with HIV-1. Out of a total of 624, we studied 182 children who survived longer than 5 years (long-term survivors [LTS]) and 120 children who died of HIV-1-related disease before 5 years (defined as short-term survivors [STS]). 28 (15%) LTS were symptomless (Centers for Disease Control [CDC] P-1 children). 154 (85%) had symptoms (CDC P-2). The proportion of LTS with less than 0.2 x 10(9)/CD4 cells per L was 24/116 (21%) at 61-72 months, rising to 11/26 (41%) at more than 96 months. On at least one occasion, p24 antigenaemia was observed in 112 (62%) LTS. Annual rate of CD4 cell loss was lower in LTS (25% [95% CI: 21-29]) than in STS (53% [45-60]) and in LTS symptomless or with solitary P-2A signs (17%; [13-21]) than in LTS with severe manifestations (30% [25-35]). A new outlook emerges. A substantial number of children do survive after early childhood; severe diseases; low CD4 cell numbers, and p24 antigenaemia do not necessarily preclude long-term survival. The study shows that a CD4 cell decrease early in life can be predictive of outcome.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD4-Positive T-Lymphocytes*
  • Child, Preschool
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • HIV Core Protein p24 / blood*
  • HIV Infections / blood*
  • HIV Infections / classification
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Infections / mortality*
  • HIV Infections / transmission
  • HIV-1*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Infant
  • Infant, Newborn
  • Italy / epidemiology
  • Leukocyte Count
  • Linear Models
  • Male
  • Population Surveillance*
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • Survival Analysis
  • Survival Rate
  • Time Factors
  • Zidovudine / therapeutic use

Substances

  • HIV Core Protein p24
  • Immunoglobulins, Intravenous
  • Zidovudine